The phosphoinositide 3 kinase AKT mammalian target of rapamycin (PI3K-AKTmTOR)
signaling pathway is an important in the aetiology of pancreatic cancer (PC) and is …

Although pancreatic cancer (PC) was considered in the past an orphan cancer type due to
its low incidence, it may become in the future one of the leading causes of cancer death …

Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …

Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently
needed. Mutations of the KRAS oncogene occur frequently in pancreatic cancer and …

Background The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in
pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an important …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterized
by its sudden manifestation, rapid progression, poor prognosis, and limited therapeutic …

Standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC), nab-paclitaxel
(NPT) plus gemcitabine (Gem), has led to an average survival of 8.5 months. Presently, no …

Background: Ras signalling is frequently aberrant in pancreatic cancer so that there is
constitutive activation of the phosphatidylinositol 3-kinase (PI3K) and AKT/protein kinase B …

Simple Summary Pancreatic cancer has a dismal 5-year survival rate of 10%, making it one
of the deadliest forms of malignancy. The poor prognosis associated with this disease is …

Abstract The phosphatidylinositol 3′-kinase (PI3k)-AKT survival pathway is activated in
many malignancies. We observed constitutive AKT phosphorylation (on S473) consistent …